GBS has inked a deal to acquire Intelligent Fingerprinting, a developer of point-of-care diagnostic screening technology for opioids and drugs of abuse.
The acquisition would enable the combination of Intelligent Fingerprinting's sweat-based drug screening technology with the GBS saliva-based glucose biosensor platform and manufacturing expertise, GBS said.
Intelligent Fingerprinting's drug screening system is a 10-minute test that analyzes fingerprint sweat to screen for recent drug use, consisting of a portable reader and single-use disposable cartridges.
Under terms of the agreement, GBS has until December 31 to evaluate and negotiate the transaction.
